Nearly half of the children receiving intranasal midazolam for laceration repair in the emergency department (ED) exhibited extreme procedural anxiety. Younger age, reduced sociability, and extremity ...

Proximagen announced promising data from the pivotal Phase 3 trial of USL261 (intranasal midazolam) for the rescue treatment of seizure clusters. The primary efficacy endpoint was treatment success, ...

AUSTIN, Texas — For acute seizure emergencies in children, intranasal midazolam is as safe and effective as intravenously or rectally administered diazepam, according to a systematic review of ...

Objective: To evaluate the feasibility of a sedation protocol based on Lidocaine spray and Intranasal Midazolam (INM) administered by Mucosal Atomizer Device (MAD) in uncooperative children undergoing ...

Intranasal midazolam is an effective alternative to the oral version for children undergoing dental treatments, according to a new study. Researchers found that when dentists administered the drug ...

Patients treated with 5-mg midazolam nasal spray were more likely than those given placebo to remain seizure free for 6 hours after treatment or have their seizure terminated within 10 minutes, with ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Intranasal ...

The NDA includes data from the Phase 3 ARTEMIS 1 trial which evaluated the intranasal spray in 292 patients. The Food and Drug Administration (FDA) has accepted for review the New Drug Application ...

Débora P. H. Schaffer, Nayone L. L. C. de Araújo, Ana Cláudia S. Raposo, Emanoel F. Martins Filho, João Victor R. Vieira and Arianne P. Oriá Safe and effective sedation protocols are important for ...

The Multidisciplinary Committee of Experts (MDC), which advices the National Pharmaceutical Pricing Authority (NPPA) on price related matters, recommended obtaining views from the Standing National ...

Saddle Brook, NJ-based Intranasal Therapeutics has changed its name to Ikano Therapeutics and closed a second and final $9 million tranche in its Series B round. The close followed Ikano's ...